<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=875423625897521&amp;ev=PageView&amp;noscript=1">

Get Fresh Updates on Email

We'll never share your email address and you can opt out at any time, we promise

Clinical Indicators of End-Stage Renal Disease (USRDS) 2018

By Susan Eymann, MS | 04 Dec 2019

(Gleaned from the 2018 USRDS Annual Data Report: Volume II: Chapter 2)

Given the high morbidity and mortality of individuals with end-stage renal disease (ESRD) who are receiving dialysis, quality improvement of renal replacement therapies (RRT) initiatives has long been a priority. Notable efforts from the Centers for Medicare & GettyImages-1132248020Medicaid Services (CMS) include assessment and reporting of provider performance through Dialysis Facility Reports and Dialysis Facility Compare, as well as the Quality Incentive Program (QIP), which ties Medicare reimbursement to the achievement of selected quality targets.

Nevertheless, preventive care for ESRD patients has declined since 2010. In 2010, 36.4 percent of diabetic ESRD patients had comprehensive diabetes monitoring that included an A1c test, lipid exam and a diabetic eye exam. However, by 2016 only 28.8 percent of diabetic ESRD patients received comparable comprehensive diabetes monitoring.

New call-to-action